Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956566 | 0.81 | PTPRC (0.49) | CES1PTPRCALDH1A1HPGDKDM4E | |
| SCHEMBL7898463 | 0.80 | CES1 (0.43) | CES1PTPRCALDH1A1HPGDKDM4E | |
| SCHEMBL29349820 | 0.77 | PTPRC (0.57) | CES1PTPRCALDH1A1HPGDKDM4E | |
| SCHEMBL1118356 | 0.77 | PTPRC (0.57) | CES1PTPRCALDH1A1HPGDKDM4E | |
| SCHEMBL10630646 | 0.76 | PTPRC (0.52) | CES1PTPRCALDH1A1HPGDKDM4E | |
| Hydrochloric Acid SCHEMBL29415866 | 0.75 | PTPRC (0.55) | CES1PTPRCALDH1A1HPGDKDM4E | |
| Hydrochloric Acid SCHEMBL27713616 | 0.75 | PTPRC (0.55) | CES1PTPRCALDH1A1HPGDKDM4E | |
| Anthracene SCHEMBL27939488 | 0.75 | PTPRC (0.55) | CES1PTPRCALDH1A1HPGDKDM4E | |
| Methane SCHEMBL27586780 | 0.75 | PTPRC (0.55) | CES1PTPRCALDH1A1HPGDKDM4E | |
| SCHEMBL29391697 | 0.74 | PTPRC (0.53) | CES1PTPRCALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354947-B2 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-04-08 | — | — | US | disclosed |
| US-6987184-B2 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-01-17 | — | — | US | disclosed |
| US-20060004080-A1 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto | SAKATA STEVEN T | 2006-01-05 | — | — | US | disclosed |
| US-20040092562-A1 | Methods for treating inflammatory conditions or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC. | 2004-05-13 | — | — | US | disclosed |
| EP-1363891-A2 | ANTHRONE DERIVATIVES AND THEIR USE AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030073732-A1 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002066450-A2 | ANTHRONE DERIVATIVES AND THEIR USE AS INK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092562-A1 | Methods for treating inflammatory conditions or inhibiting JNK | TNF, MAPKAPK2, CHUK | CES1 1830/4885PTPRC 326/4885ALDH1A1 2133/4885 |
| US-20060004080-A1 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto | MAPK7, MAP3K7, MAP3K21 | CES1 3435/4885PTPRC 987/4885ALDH1A1 1957/4885 |
| US-20030073732-A1 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAPKAPK2, MAP3K2 | CES1 2033/4885PTPRC 893/4885ALDH1A1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.